Inactive Instrument

Highlights Therapix Biosciences Ltd. Nasdaq

Equities

US88339A2033

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd.	11/04	CI
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
SciSparc Ltd. Receives Another Patent, Strengthening its Core Technology in Canada	18/03	CI
SciSparc Ltd. Announces Successfully Dosed the First Patient in Its SCI-210 Clinical Trial At the Soroka Medical Center for Pediatric Patients	14/03	CI
SciSparc Ltd. Announces Enrollment of First Patient for Its Clinical Trial for Children with Autism Spectrum Disorder	08/03	CI
Scisparc Ltd. Granted Patent for Core Technology in Multiple Jurisdictions in Europe	07/03	CI
SciSparc Ltd. Receives Canadian Patent for Opioids Reduction Use in Pain Management Technology	07/03	CI
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	29/02	CI
Clearmind Medicine Submits Three International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds	27/02	MT
Clearmind Medicine Submits Three International Patent Applications for Next Generation Psychedelic-Based Compounds	20/02	MT
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder	29/01	CI
SciSparc Ltd. and Clearmind Medicine Inc. Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments	04/01	CI
Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial	01/12	CI
SciSparc Ltd. Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment	28/11	CI
SciSparc Signs Letter of Intent to Merge With Vehicle Importer in Israel	22/11	MT
An unknown buyer signing of a non-binding letter of intent to acquire SciSparc Ltd. in reverse merger transaction.	22/11	CI
SciSparc Ltd. Unveils Positive Topline Results from its Investigator-Initiated Phase IIa Trial At the Sophie & Abraham Stuchynski Israeli Alzheimer's Medical Center	15/11	CI
SciSparc Ltd. Announces Initiation of its Phase IIb Clinical Trial Treatments with its SCI-110, Proprietary Drug Candidate	10/11	CI
SciSparc Ltd. Receives Patent from the Australian Patent Office for Its Reduction of Opioids Use in Pain Management Technology	31/23/31	CI
SciSparc Ltd. Receives Notice of Acceptance for Its Core Technology Application for the Combinations of Cannabinoids and N-Acylethanolamines	24/23/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Therapix Biosciences Ltd. Nasdaq

Equities

US88339A2033

Highlights

Filters